134
Views
8
CrossRef citations to date
0
Altmetric
Research Article

Integrin αIIbβ3 exists in an activated state in subjects with elevated plasma homocysteine levels

, , , , , , , & show all
Pages 63-71 | Received 23 Mar 2010, Accepted 29 Jul 2010, Published online: 06 Dec 2010
 

Abstract

Elevated levels of plasma homocysteine (Hcy) are an independent risk factor for cardiovascular disease and thrombosis. The molecular basis for this phenomenon is not known but may relate to modification of cell surface thiols. The platelet specific integrin αIIbβ3 is a cysteine-rich cell adhesion molecule that plays a critical role in platelet aggregation and adhesion in haemostasis and thrombosis. In this study, we looked for evidence of a homocysteine-induced modification of αIIbβ3 using a fluorescently labeled PAC-1 antibody that recognizes the activated conformation of the integrin on the platelet surface. We show that exogenous Hcy (10–100 µM) and homocysteine thiolactone (HcyTL) (10–100 µM) increased PAC-1 binding to platelets in a concentration dependent manner in vitro. In parallel, we show subjects with clinical hyperhomocysteinemia exhibit a greater degree of activation of αIIbβ3 compared to age-matched controls. These findings demonstrate that circulating Hcy can modulate the activation state of the platelet integrin αIIbβ3, a key player in platelet aggregation and thrombosis.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.